Acadia Pharmaceuticals has handed the market a clinical-development story with no tidy ending. Its Phase 2 RADIANT study of remlifanserin in Alzheimer’s-related psychosis narrowly missed the primary endpoint, while a key secondary endpoint reached nominal significance—a split decision that may keep investors in $ACAD focused less on celebration and more on what comes next.
The stakes are meaningful because Alzheimer’s psychosis remains a large unmet market with no FDA-approved treatment, according to the supplied story context. But the RADIANT readout does not establish Phase 3 efficacy or represent a regulatory success. Instead, it leaves Acadia carrying both a warning flag and a future catalyst.
A primary endpoint miss with a narrow margin
The primary endpoint produced a p-value of 0.0603. Acadia characterized the result as a narrow miss, but that distinction does not erase the central fact: the study did not achieve its primary endpoint.
For healthcare investors, the primary endpoint is the main analytical checkpoint in a clinical trial. Missing it can complicate the path ahead, even when other measurements point in a favorable direction. In this case, the result creates near-term uncertainty around how confidently the Phase 2 evidence supports continued development and how the market will weigh the program’s prospects.
That uncertainty is especially important for $ACAD because the company is asking investors to look beyond an incomplete Phase 2 scorecard. The p-value of 0.0603 is close to the conventional statistical threshold often used in clinical research, but “close” is not the same as meeting the primary endpoint. The distinction may keep scrutiny high as the program advances.
The secondary endpoint keeps the story alive
RADIANT also delivered a more encouraging signal: a key secondary endpoint reached nominal significance, with a p-value of 0.0077. That result gives Acadia a substantive data point to carry into the next stage, even though it cannot substitute for success on the primary endpoint.
Nominal significance may suggest that remlifanserin is affecting an important measure in Alzheimer’s-related psychosis. Still, the result needs to be viewed alongside the primary endpoint miss rather than treated as a clean victory. The mixed pattern is precisely why the readout matters: it offers enough support to preserve the development narrative, but not enough to remove the clinical questions.
Acadia’s decision to continue Phase 3 development makes that tension the central investment theme. The company has not closed the door after the Phase 2 result; it is keeping the program moving toward a larger and potentially more definitive test. That decision preserves a future catalyst tied to Phase 3, while also ensuring that upcoming development milestones may face heightened attention.
Why the market may stay cautious
For $ACAD investors, the immediate takeaway is not that Phase 3 efficacy has been established. It has not. The more measured conclusion is that the program remains viable enough for Acadia to continue, supported by the key secondary endpoint but constrained by the primary endpoint miss.
That creates a familiar healthcare-investor balancing act. The unmet need is large, and a treatment for Alzheimer’s psychosis could address a market with no FDA-approved option. Yet the route from a mixed Phase 2 result to a successful regulatory outcome remains uncertain. Phase 3 development may clarify whether the secondary signal is durable and clinically meaningful, or whether the primary-endpoint result was an early warning.
Acadia’s additional RADIANT data, reported in the company’s study presentation, therefore leaves $ACAD at a crossroads rather than a finish line. The p-value of 0.0077 supplies a reason to keep watching. The p-value of 0.0603 supplies an equally clear reason to remain disciplined about what is—and is not—known.
That is the catalyst-watch setup: uncertainty in the near term, with Phase 3 still on the horizon. Investors may continue to debate the weight of the secondary endpoint, but the next major test belongs to the company’s ongoing Phase 3 program.
Bull/Bear Verdict
Bull Case: The key secondary endpoint’s nominal significance at p=0.0077 may support continued development, while the large unmet need in Alzheimer’s psychosis and Acadia’s decision to proceed into Phase 3 preserve a meaningful future catalyst for $ACAD.
Bear Case: The primary endpoint miss at p=0.0603 may keep near-term uncertainty elevated, and the mixed Phase 2 readout does not establish Phase 3 efficacy or a regulatory success.